Friday Aug 29
Covance Given Consensus Recommendation of "Buy" by Analysts
Covance has been given an average recommendation of "Buy" by the fifteen ratings firms that are currently covering the company, StockRatingsNetwork.com reports .
Covance Receives Average Rating of "Buy" from Analysts
Covance has been given an average rating of "Buy" by the fifteen brokerages that are presently covering the stock, Analyst RN reports .
Top CROs dominate competition in trial totals, review finds
A breakdown of trials run by the top contract research organizations reveals that the big players are leaving little room for smaller firm to compete, according to a review by Outsourcing-Pharma.com of trials in clinicaltrials.gov.
New Market Report: Covance Inc. (CVD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Covance Inc. is drug development service company. The company offers a broad range of early-stage and late-stage product development services principally to the pharmaceutical and biotechnology industries.
Covance Inc. Partners With To Provide Free Health Care To Wisconsin??'s Uninsured Patients
Covance Inc. , the world's most comprehensive drug development company and a leader in nutritional analysis, partnered with the National Association of Free and Charitable Clinics for a third year to support a day-long clinic where uninsured and underinsured patients in the Madison, Wisconsin, area were given access to free medical attention.